{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:22:34Z","timestamp":1787505754747,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T00:00:00Z","timestamp":1419638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2015,2]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n \n P<\/jats:styled-content>\n seudomonas aeruginosa\n <\/jats:italic>\n , especially multidrug\u2010resistant (\n MDR<\/jats:styled-content>\n ) isolates, is an important pathogen in allogeneic hematopoietic stem cell transplant (\n HCT<\/jats:styled-content>\n ) recipients. The ability to identify patients at risk for these infections and administer appropriate empiric therapy, particularly during episodes of neutropenia, may improve outcomes and also direct infection control and antimicrobial stewardship efforts. Many transplant centers obtain routine surveillance stool cultures (\n SSC<\/jats:styled-content>\n s) from\n HCT<\/jats:styled-content>\n recipients to test for colonization with vancomycin\u2010resistant enterococci, and extended\u2010spectrum beta lactamase\u2010producing Enterobacteriaceae. Our center initiated the performance of\n SSC<\/jats:styled-content>\n s for\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n , because of a perceived increase in the frequency of infection with\n MDR<\/jats:styled-content>\n strains. The aim of this study was to determine the utility of this practice.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We conducted a 2\u2010year (2010\u20132011) retrospective review of the medical records of all patients who underwent allogeneic\n HCT<\/jats:styled-content>\n at our cancer center to (a) determine the frequency of fecal colonization with\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n , including\n MDR<\/jats:styled-content>\n strains; (b) to determine the overall frequency of subsequent\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n infection, as well as the frequency of infection with\n MDR<\/jats:styled-content>\n strains; (c) to ascertain the proportion of subsequent infections likely arising from the intestinal tract; and (d) to determine risk factors for progression from colonization to infection.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 794 study patients, 58 (7.3%) had at least 1 positive\n SSC<\/jats:styled-content>\n for\n \n P<\/jats:styled-content>\n <\/jats:italic>\n .\u00a0\n aeruginosa;<\/jats:italic>\n 19\/58 (32.8%) developed a subsequent pseudomonal infection (11 with matching antimicrobial resistance patterns). On the other hand, 37\/736 (5%) of the patients who were not colonized, developed a pseudomonal infection. The type of infection observed was pneumonia in 26 (46%) patients, bloodstream infection in 20 (36%), urinary tract infection in 8 (14%), and infections at other sites in 2 (4%). The incidence of\n MDR<\/jats:styled-content>\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n in the entire cohort was 2.2% (18 of 794): 12 had positive\n SSC<\/jats:styled-content>\n s and 7 of these patients later developed\n MDR<\/jats:styled-content>\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n infections. Patients with acute myelogenous leukemia were more likely to be colonized and to develop subsequent infection. No infection\u2010related deaths were observed during the first 30\u00a0days after infection.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The incidence of\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n colonization and subsequent infection was low. Patients who were not colonized had a low chance of developing\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n infection. Most patients who developed infection did not have fecal colonization, suggesting a different source of infection.\n SSC<\/jats:styled-content>\n s for\n \n P<\/jats:styled-content>\n .\u00a0aeruginosa\n <\/jats:italic>\n provide incomplete information regarding the source of infection.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/tid.12323","type":"journal-article","created":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T00:45:16Z","timestamp":1419641116000},"page":"33-38","source":"Crossref","is-referenced-by-count":55,"title":["Fecal colonization and infection with\n \n P<\/scp>\n seudomonas aeruginosa\n <\/i>\n in recipients of allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1111","volume":"17","author":[{"given":"L.","family":"Nesher","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.V.I.","family":"Rolston","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"Tarrand","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Mulanovich","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Ariza\u2010Heredia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Chemaly","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,27]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir492"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0229-y"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02561-14"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000329661"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24812"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis580"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2006.04.205"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-012-0269-y"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.03.001"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhin.1999.0740"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1875-9572(09)60024-3"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.42.1072"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197008000-00002"},{"key":"e_1_2_5_16_1","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical Laboratory Standards Institute","year":"2010"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0525-9"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705653"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/520247"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/427331"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.67.118"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12323","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T14:18:25Z","timestamp":1695478705000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,27]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/tid.12323"],"URL":"https:\/\/doi.org\/10.1111\/tid.12323","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,27]]}}}